Foundayo Cost and Savings Card: What Each Dose Costs

Foundayo is orforglipron, the first oral small-molecule GLP-1, and it arrived with the most aggressive pricing of any branded GLP-1 in the United States. Self-pay starts at $149 a month and tops out at $349 — against $299 to $699 for Zepbound.

That is the headline, and it is real. What follows are the three conditions attached to it, none of which is in the headline.

What each dose costs

These are Eli Lilly's own figures for a one-month supply, where a month is defined as 30 days.

Read the two right-hand columns together and the card does one thing for self-payers: it takes $50 off the top two doses. At every dose below 14.5 mg the card price and the regular price are the same number, which means the card is worth nothing at all until you titrate past 9 mg.

That is worth knowing before you spend time enrolling. It is also the opposite of how these programmes are usually described.

The 45-day rule

The $299 price on 14.5 mg and 17.2 mg is not a standing price. It is a purchase offer that applies automatically on your first fill at those doses, and to keep it you must refill within 45 days of the delivery or receipt date of your previous fill. Miss the window and the price returns to $349.

Fifty dollars is less punishing than the equivalent Zepbound rule, where the same 45-day condition governs a $250 swing — see the Zepbound savings card. But the trap is identical, and the two most common reasons for missing the window are the same: a dose change that needs a new prescription, and a pharmacy or shipping delay.

The practical answer is also the same. Order on day 25 to 30 rather than when the bottle runs out.

Ten fills a year, on a daily medication

This one is easy to miss and nobody states its consequence.

The card may be used for a maximum of ten prescription fills per calendar year, and a fill is 30 days. Foundayo is taken once daily, continuously. Ten fills of 30 days is 300 days.

So roughly two months of a full year's treatment fall outside the card. If you are budgeting on the card price, budget ten months of it and two months of something else.

If you have commercial insurance that covers Foundayo

Then the picture changes entirely: as little as $25 a month, for a one-, two- or three-month fill.

As always, "as little as" is doing work. Savings are capped at $100 per one-month fill, $200 per two-month, $300 per three-month, and — the number that binds — $1,000 per calendar year.

So $25 is reachable only if your plan already leaves you owing $125 or less, and the annual cap is lower than Zepbound's $1,300. On a plan with a meaningful cost-share you will exhaust the $1,000 before the year is out and pay full freight after that.

The Medicare exception, which is genuinely unusual

The standing rule across every manufacturer copay programme in the United States is that government beneficiaries are excluded. Medicare, Medicaid, TRICARE, the VA — federal anti-kickback law prohibits manufacturer copay assistance for all of them, so this is not one company being restrictive.

Foundayo carries an exception: participation in the Medicare GLP-1 Bridge Program at $50 a month.

That is not the savings card. It is a separate federal arrangement, and it matters because the group normally locked out of every discount is also the group most likely to be on a fixed income. If you are on Medicare and have been told the manufacturer card cannot help you, that is true of the card and not true of the bridge. Our guide to Medicare coverage of GLP-1s covers how the bridge works and who qualifies.

How it compares

Against the other branded self-pay routes, at the doses people actually maintain on:

Foundayo is the cheapest at the top of the range by a wide margin — $349 against Zepbound's $699 — which is the comparison that matters, because that is where people end up rather than where they start.

Price is not the only axis, and it should not be the deciding one. Zepbound produced roughly 20.9% average weight loss in SURMOUNT-1; the oral options have not matched that. What has changed is that cost is no longer the reason to rule Foundayo out. See the full Foundayo guide for what the phase 3 evidence actually shows, and our cost index for every route side by side.

What to check before you rely on any of this

• The card expires 31 December 2026. Manufacturer programmes are re-issued annually with revised amounts and conditions, so any figure here should be re-checked rather than assumed into next year.
• You need a prescription for an approved use. The terms require the prescription be consistent with FDA-approved labelling, which is the condition that catches off-label prescribing.
• Government coverage excludes you from the card, though not necessarily from the bridge.
• Lilly may change or cancel the terms at any time, at its sole discretion and without notice. That is in the terms, and it is not boilerplate — the Zepbound tiers moved twice this year.

The other manufacturer savings programmes work on the same pattern and differ in the details that matter: Zepbound, Wegovy, Mounjaro and Foundayo, which is the cheapest of the four.

This article is educational and is not medical or financial advice. Every figure was read from Lilly's own coverage and savings page on 10 August 2026, terms and footnotes included. Programme terms change frequently and Lilly reserves the right to amend them without notice; confirm current details before budgeting around them.